Normalizing Healthiness - Sustainability

Improving Accessibility and Affordability of Pharmaceuticals

Nearly 80 Countries and Regions 39 Overseas Certifications 81 Overseas Registrations: The Group is actively expanding its international business and optimizing its global industrial footprint. The sales network of the Group spans across the globe, covering nearly 80 countries and regions including China, Europe, India, the Middle East, South America, and Southeast Asia, encompassing all major pharmaceutical markets as well as emerging markets. The intermediate products and bulk medicine of the Group have obtained official certifications from the European Union CEP, the United States FDA, Germany, India, Japan, Brazil, Mexico, among other countries. Currently, we hold 39 overseas certifications and 81 overseas registrations.

67 products have been included in the National Medical Insurance Drug List (2024 edition) 31 products have been included in the National Essential Drug List (2018 edition): The Group is actively participating in the national centralized procurement of drugs, with multiple products, notably our full line of insulin products, being selected in the national bidding. This further expands the supply of affordable and high-quality pharmaceuticals, delivering sustained benefits to a broader patient population. Moreover, the Group is committed to enhancing drug accessibility in developing countries by establishing fair and reasonable pricing mechanisms, ensuring relatively transparent and consistent pricing strategies across different markets.

Enhancing Healthcare Standards

Advancing Pharmaceutical Academia

The Group is committed to advancing the pharmaceutical industry by actively participating in medical academic forums such as the Annual Meeting of the Diabetes Committee of the Chinese Research Hospital Association and the Annual Meeting of the Clinical Pharmacy Committee of the Chinese Medical Association. We also continue to support and co-organize the 「Dual Excellence Initiative」 series of training programs focused on primary-level diabetes prevention and management.

Safeguarding Public Health

Adhering to the tenant 「To Make Life More Valuable」, the Group supports the provisions of the Doha Declaration on the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and Public Health that safeguard public health and implement compulsory licensing of patents during emergencies.

Advocating for Fair Competition

As a generic drugs manufacturer, the Group advocates for reasonable generic drugs competition to promote the healthy development of the pharmaceutical market.

Improving Pharmaceutical Standards

The Group is committed to improving pharmaceutical manufacturing standards in developing countries by offering technical process improvement support, thereby enabling drug manufacturers to boost production efficiency and ensure product quality compliance to meet regulatory market requirements and international pharmaceutical manufacturing standards.

Promoting Rational Use of Antibiotics

In response to antibiotic resistance issues caused by misuse and overuse, the Group strictly complies with national regulations on antimicrobial management and actively promotes the rational use of antibiotics to reduce the occurrence of antibiotic misuse. Meanwhile, to combat antibiotic resistance, the Group is engaged in R&D of drugs targeting drug-resistant bacterial infections.

Focusing on Rare Diseases

Guided by policies such as the Drug Registration Management Measures and the Rare Disease Diagnosis and Treatment Guidelines, the Group leverages its scientific research strengths to actively respond to national policies. We conduct in-depth analyses of market demand for rare diseases, increase R&D investment, and are committed to improving the current state of clinical treatment for rare diseases in China. The Group is dedicated to enhancing the accessibility of innovative drugs for patients with rare diseases, enabling more patients to benefit.